A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)
Authors
Ahrens, MEscudier, B
Boleti, E
Grimm, MO
Goupir, MG
Barthelemy, P
Gravis, G
Bedekes, J
Ivanyi, P
Panic, A
Zschabitz, S
Neyrieru, S
Mellado, B
Bie, A
Wadell, Tom
Maroto, JP
Retz, M
Boegemann, M
Rottey, S
Haanen, J
Oosting, S
Castellano, D
Hartmann, A
Bergmann, L
Affiliation
Uniklinik Frankfurt, Med. Klinik II, FrankfurtIssue Date
2020